Market research
PCJP.F Abeona Therapeutics Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 29M
- P/E ratio
- Not available
- Analyst target
- 5
- Dividend yield
- 0.0%
- Beta
- 1.5
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 29M
- P/E ratio
- Not available
- Analyst target
- 5
- Dividend yield
- 0.0%
- Beta
- 1.5
About
About Abeona Therapeutics Inc
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PCJP.F discussion.
5 years, 4 months ago
Abeona Therapeutics Inc is currently in a long term downtrend where the price is trading 15.7% below its 200 day moving average.
From a valuation standpoint, the stock is 98.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 17.1.
Abeona Therapeutics Inc's total revenue rose by inf% to $3M since the same quarter in the previous year.
Its net income has increased by 3.7% to $-16M since the same quarter in the previous year.
Finally, its free cash flow grew by 88.6% to $-2M since the same quarter in the previous year.
Based on the above factors, Abeona Therapeutics Inc gets an overall score of 4/5.